NCT05242003: Assessing the Safety and Efficacy of MYMD1 to Treat Depression in Patients With Post-Acute Sequelae of Coronavirus Disease-2019 (PASC) |
|
|
| Not yet recruiting | 2 | 90 | US | Placebo, 300mg MYMD-1, 88139462, 600mg MYMD-1 | Johns Hopkins University, MyMD Pharmaceuticals, Inc. | Depression, Anxiety, Inflammation, COVID-19 | 10/22 | 03/23 | | |
NCT05283486: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty |
|
|
| Completed | 2 | 40 | US | MYMD-1 600MG, MYMD1 600mg, MYMD-1 750mg, MYMD1 750mg, MYMD-1 900mg, MYMD1 900mg, MYMD-1 1050mg, MYMD1 1050mg, placebo 600mg, placebo-600mg, placebo 750mg, placebo-750mg, placebo 900mg, placebo-900mg, placebo 1050mg, placebo-1050mg | MyMD Pharmaceuticals, Inc. | Sarcopenia, Frailty, Aging | 06/23 | 06/23 | | |
